News
Hims & Hers stock plummets after Novo Nordisk ends Wegovy direct sales deal
Hims & Hers ( HIMS) stock plummeted around 30% in early trading Monday after Novo Nordisk ( NVO) announced it was ending a collaboration to make its blockbuster weight-loss drug, Wegovy, available on Hims' telehealth platform.
The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...
30m
Novo Nordisk ends partnership with Hims & Hers over compounded Wegovy, shaking the market. See why I recommend a wait-and-see ...
After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...
Shares in Novo Nordisk fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema ...
Occidental Petroleum (OXY): Energy stocks gained modestly ...
Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback